Cited by 404Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice

Open access
Zhang, Bin, Carroll, Jenna, Trojanowski, John Q., Yao, Yuemang, Iba, Michiyo, Potuzak, Justin S., Hogan, Anne-Marie L., Xie, Sharon X. +4 more·2012·The Journal of Neuroscience

Abstract

Neurodegenerative tauopathies, such as Alzheimer's disease (AD), are characterized by insoluble deposits of hyperphosphorylated tau protein within brain neurons. Increased phosphorylation and decreased solubility has been proposed to diminish normal tau stabilization of microtubules (MTs), thereby leading to neuronal dysfunction. Earlier studies have provided evidence that small molecule MT-stabilizing drugs that are used in the treatment of cancer may have utility in the treatment of tauopathies. However, it has not been established whether treatment with a small molecule MT-stabilizing compound will provide benefit in a transgenic model with pre-existing tau pathology, as would be seen in human patients with clinical symptoms. Accordingly, we describe here an interventional study of the brain-penetrant MT-stabilizing agent, epothilone D (EpoD), in aged PS19 mice with existing tau pathology and related behavioral deficits. EpoD treatment reduced axonal dystrophy and increased axonal MT density in the aged PS19 mice, which led to improved fast axonal transport and cognitive performance. Moreover, the EpoD-treated PS19 mice had less forebrain tau pathology and increased hippocampal neuronal integrity, with no dose-limiting side effects. These data reveal that brain-penetrant MT-stabilizing drugs hold promise for the treatment of AD and related tauopathies, and that EpoD could be a candidate for clinical testing.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.4922-11.2012

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several studies have suggested that oligomeric tau in soluble forms may be the most potent neurotoxic form.

    “Although tau aggregates are hallmarks of AD, several studies have suggested that oligomeric tau in soluble forms may be the most potent neurotoxic form 68–73.”

    From Amyloid-beta induced retrograde axonal degeneration in a mouse tauopathy model (2019) · cites this paper as [73]

    The Introduction (page unavailable) identifies insoluble tau aggregates in Alzheimer’s disease, and the Discussion (page unavailable) links misfolded tau generally to neurodegeneration. Neither passage addresses whether soluble oligomeric tau is the most potent neurotoxic form. Searches for oligomers and comparative toxicity found no passage making that point. (LLM, conf=0.74)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

4 of the 67 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. [15]Cleveland DW Connolly JA Kalnins VI Spiegelman BM Kirschner MW 1977a Physical properties and cellular localization of tau, a microtubule-associated protein which induces assembly of purified tubulin Journal of Cell Biology 75 A283

Cited by

Sorted by citations

Authors
Zhang, B., Carroll, J., Trojanowski, J. Q., Yao, Y., Iba, M., Potuzak, J. S., Hogan, A.-M. L., Xie, S. X., Ballatore, C., Smith, A. B., Lee, V. M.-Y., & Brunden, K. R.
Affiliations
  • University of Pennsylvania (US)
  • Institute on Aging (US)
Corresponding author
Brunden, Kurt R.
Venue
The Journal of Neuroscience
Published
2012-03-14
Volume
32
Issue
11
Pages
3601-3611
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W1969129718
Cited by
401
References
67
Citations by year
2026: 18 · 2025: 19 · 2024: 22 · 2023: 11 · 2022: 31 · 2021: 36 · 2020: 37 · 2019: 24 · 2018: 27 · 2017: 28 · 2016: 44 · 2015: 26 · 2014: 40 · 2013: 23 · 2012: 14
FWCI
22.08
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Bristol-Myers Squibb
  • University of Pennsylvania
  • National Institutes of Health
  • National Institute on Aging (U01AG029213)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
epothilone D, microtubule stabilization, tauopathy, Alzheimer's disease, tau phosphorylation, axonal dystrophy, axonal transport, cognitive impairment, hippocampal neurons, PS19 mice, neuroprotection, drug repurposing
MeSH terms
Aging, Alzheimer Disease, Animals, Axons, Cognition Disorders, Humans, Male, Mice, Transgenic, Microtubules, tau Proteins, Neurotoxicity Syndromes, Tauopathies, Epothilones, Tubulin Modulators, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review